Dick White Referrals, Station Farm, Suffolk, UK.
Davies Veterinary Specialists, Manor Farm Business Park, Hertfordshire, UK.
Vet Comp Oncol. 2016 Dec;14(4):361-370. doi: 10.1111/vco.12116. Epub 2014 Sep 15.
This retrospective case series evaluates survival outcome of 94 dogs with high metastatic risk mast cell tumours (MCT). Patients were treated with a cytotoxic chemotherapy protocol or the tyrosine kinase inhibitor masitinib, in the presence of gross disease or as an adjunct to surgical resection of the primary tumour. In patients presenting with metastatic disease, surgical resection of the primary tumour with adjunctive therapy with any chemotherapy incurred a significant survival advantage [median survival time (MST): 278 days] compared to patients receiving chemotherapy without surgical excision of the primary tumour (MST: 91 days, P < 0.0001). Patients with a surgically excised Patnaik grade II tumour and high Ki-67 in the absence of metastatic disease treated with vinblastine and prednisolone showed a significantly longer survival (MST: 1946 days) than those treated with masitinib (MST: 369 days, P = 0.0037). Further prospective case-controlled clinical trials of high-risk MCTs are required to make precise evidence-based treatment decisions for individual patients.
本回顾性病例系列评估了 94 例高转移风险肥大细胞瘤 (MCT) 犬的生存结果。在存在明显疾病或作为原发性肿瘤切除的辅助治疗时，患者接受细胞毒性化疗方案或酪氨酸激酶抑制剂马替尼治疗。对于患有转移性疾病的患者，与未接受原发性肿瘤切除的化疗患者相比（MST：91 天，P < 0.0001），接受原发性肿瘤切除和辅助治疗的任何化疗药物的患者具有显著的生存优势（MST：278 天）。对于接受长春碱和泼尼松龙治疗且无转移疾病且手术切除 Patnaik 分级 II 肿瘤和高 Ki-67 的患者，其生存时间明显更长（MST：1946 天），而接受马替尼治疗的患者（MST：369 天，P = 0.0037）。需要进一步进行高风险 MCT 的前瞻性病例对照临床试验，以便为个体患者做出精确的基于证据的治疗决策。
